Yi Liu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Yi Liu has a total of 88 co-authors. Here are the top co-authors by number of shared publications:
- Xiangsheng Zuo
Department of Gastrointestinal Medical Oncology, University of Texas MD Anderson Cancer Center
7 shared publications - Imad Shureiqi
Division of Hematology and Oncology, Department of Internal Medicine, University of Michigan, USA; Rogel Cancer Center, University of Michigan, USA
5 shared publications - Daoyan Wei
Department of Gastroenterology and Hepatology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
4 shared publications - Huamin Wang
Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
2 shared publications - James C. Yao
Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
2 shared publications - Jonathan Jaoude
Departments of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas
2 shared publications
Latest Publications
- 27 February 2026
- Published by Elsevier in Cancer Letters
- Vol. 645, 218385
PPARδ: An underappreciated tumor accelerator in pancreatic ductal adenocarcinoma
- 27 February 2026
- Published by Elsevier in Cancer Letters
- Vol. 645, 218385
PPARδ: An underappreciated tumor accelerator in pancreatic ductal adenocarcinoma
- 4 August 2025
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 31 (19) , 4018-4031
CAR-Macrophage Cell Therapy: A New Era of Hope for Pancreatic Cancer
Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest malignancies, characterized by late diagnosis, early metastasis, and resistance to conventional therapies. A major barrier to effective treatment is its desmoplastic and immunosuppressive tumor microenvironment, which restricts T-cell infiltration and dampens responses to immune checkpoint inhibitors (ICI). These features highlight the urgent need for innovative immunotherapeutic strategies capable of overcoming PDAC’s immunologic and physical barriers. Chimeric antigen receptor (CAR)-macrophage (CAR-M) therapy has emerged as a promising approach to address these challenges. Unlike CAR-T or CAR-NK cells, CAR-Ms can efficiently infiltrate tumors, remodel the tumor microenvironment, phagocytose tumor cells, and stimulate adaptive immunity. This review highlights recent advances in CAR-M therapy for solid tumors, with an emphasis on PDAC. Preclinical studies show that CAR-Ms enhance antigen presentation, secrete proinflammatory cytokines, and recruit cytotoxic T cells, thereby amplifying antitumor responses. Progress in CAR-M engineering—such as dual-targeting strategies, CRISPR-based modifications, and combinations with ICIs or other therapies—further strengthens their therapeutic potential. Importantly, early-phase clinical trials in solid tumors support the safety, tolerability, and tumor-modulating capacity of CAR-Ms, laying the groundwork for their application in PDAC. To fully harness CAR-M therapy in PDAC, several challenges must be addressed, including improving CAR-M persistence and efficacy, optimizing tumor-specific targeting, developing scalable and cost-effective manufacturing platforms, and integrating strategic combinations with other therapies, such as ICIs and KRAS inhibitors. With continued innovation and clinical validation, CAR-M therapy has the potential to transform PDAC treatment, fulfill critical unmet clinical needs, and provide new hope for patients.
- 4 August 2025
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 31 (19) , 4018-4031
CAR-Macrophage Cell Therapy: A New Era of Hope for Pancreatic Cancer
Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest malignancies, characterized by late diagnosis, early metastasis, and resistance to conventional therapies. A major barrier to effective treatment is its desmoplastic and immunosuppressive tumor microenvironment, which restricts T-cell infiltration and dampens responses to immune checkpoint inhibitors (ICI). These features highlight the urgent need for innovative immunotherapeutic strategies capable of overcoming PDAC’s immunologic and physical barriers. Chimeric antigen receptor (CAR)-macrophage (CAR-M) therapy has emerged as a promising approach to address these challenges. Unlike CAR-T or CAR-NK cells, CAR-Ms can efficiently infiltrate tumors, remodel the tumor microenvironment, phagocytose tumor cells, and stimulate adaptive immunity. This review highlights recent advances in CAR-M therapy for solid tumors, with an emphasis on PDAC. Preclinical studies show that CAR-Ms enhance antigen presentation, secrete proinflammatory cytokines, and recruit cytotoxic T cells, thereby amplifying antitumor responses. Progress in CAR-M engineering—such as dual-targeting strategies, CRISPR-based modifications, and combinations with ICIs or other therapies—further strengthens their therapeutic potential. Importantly, early-phase clinical trials in solid tumors support the safety, tolerability, and tumor-modulating capacity of CAR-Ms, laying the groundwork for their application in PDAC. To fully harness CAR-M therapy in PDAC, several challenges must be addressed, including improving CAR-M persistence and efficacy, optimizing tumor-specific targeting, developing scalable and cost-effective manufacturing platforms, and integrating strategic combinations with other therapies, such as ICIs and KRAS inhibitors. With continued innovation and clinical validation, CAR-M therapy has the potential to transform PDAC treatment, fulfill critical unmet clinical needs, and provide new hope for patients.
- Open Access
- 1 May 2024
- Published by Springer Nature in Cell Death Discovery
- Vol. 10 (1) , 1-13
TM7SF2-induced lipid reprogramming promotes cell proliferation and migration via CPT1A/Wnt/β-Catenin axis in cervical cancer cells
Cervical cancer poses a serious threat to women’s health globally. Our previous studies found that upregulation of TM7SF2, which works as an enzyme involved in the process of cholesterol biosynthesis expression, was highly correlated with cervical cancer. However, the mechanistic basis of TM7SF2 promoting cervical cancer progression via lipid metabolism remains poorly understood. Therefore, quantification of fatty acids and lipid droplets were performed in vitro and in vivo. The protein-protein interaction was verified by Co-IP technique. The mechanism and underlying signaling pathway of TM7SF2 via CPT1A associated lipid metabolism in cervical cancer development were explored using Western blotting, IHC, colony formation, transwell assay, and wound healing assay. This study reported that overexpression of TM7SF2 increased fatty acids content and lipid droplets both in vivo and in vitro experiments. While knockout of TM7SF2 obviously attenuated this process. Moreover, TM7SF2 directly bonded with CPT1A, a key enzyme in fatty acid oxidation, and regulated CPT1A protein expression in cervical cancer cells. Notably, the proliferation and metastasis of cervical cancer cells were elevated when their CPT1A expression was upregulated. Then, rescue assay identified that CPT1A overexpressed could enhance the cell viability and migration in TM7SF2-knockout cells. Furthermore, depletion of TM7SF2 significantly inhibited WNT and β-catenin proteins expression, which was enhanced by CPT1A-overexpressed. The proliferation and migration of cervical cancer cells were reversed in CPT1A-overexpressed cells with the treatment of MSAB, an inhibitor of Wnt/β-Catenin pathway. This study put forward an idea that TM7SF2-induced lipid reprogramming promotes proliferation and migration via CPT1A/Wnt/β-Catenin axis in cervical cancer, underlying the progression of cervical cancer.
- 1 May 2024
- Published by Springer Nature in Cell Death Discovery
- Vol. 10 (1) , 1-13
Open AccessTM7SF2-induced lipid reprogramming promotes cell proliferation and migration via CPT1A/Wnt/β-Catenin axis in cervical cancer cells
Cervical cancer poses a serious threat to women’s health globally. Our previous studies found that upregulation of TM7SF2, which works as an enzyme involved in the process of cholesterol biosynthesis expression, was highly correlated with cervical cancer. However, the mechanistic basis of TM7SF2 promoting cervical cancer progression via lipid metabolism remains poorly understood. Therefore, quantification of fatty acids and lipid droplets were performed in vitro and in vivo. The protein-protein interaction was verified by Co-IP technique. The mechanism and underlying signaling pathway of TM7SF2 via CPT1A associated lipid metabolism in cervical cancer development were explored using Western blotting, IHC, colony formation, transwell assay, and wound healing assay. This study reported that overexpression of TM7SF2 increased fatty acids content and lipid droplets both in vivo and in vitro experiments. While knockout of TM7SF2 obviously attenuated this process. Moreover, TM7SF2 directly bonded with CPT1A, a key enzyme in fatty acid oxidation, and regulated CPT1A protein expression in cervical cancer cells. Notably, the proliferation and metastasis of cervical cancer cells were elevated when their CPT1A expression was upregulated. Then, rescue assay identified that CPT1A overexpressed could enhance the cell viability and migration in TM7SF2-knockout cells. Furthermore, depletion of TM7SF2 significantly inhibited WNT and β-catenin proteins expression, which was enhanced by CPT1A-overexpressed. The proliferation and migration of cervical cancer cells were reversed in CPT1A-overexpressed cells with the treatment of MSAB, an inhibitor of Wnt/β-Catenin pathway. This study put forward an idea that TM7SF2-induced lipid reprogramming promotes proliferation and migration via CPT1A/Wnt/β-Catenin axis in cervical cancer, underlying the progression of cervical cancer.
- 6 July 2023
- Published by Elsevier in Gastroenterology
- Vol. 164 (6)
Sa1115 MORTALITY TRENDS IN THE UNITED STATES FOR NON-COVID-19 RELATED INTRA-ABDOMINAL INFECTIONS BEFORE AND DURING THE PANDEMIC
- 6 July 2023
- Published by Elsevier in Gastroenterology
- Vol. 164 (6)
Sa1115 MORTALITY TRENDS IN THE UNITED STATES FOR NON-COVID-19 RELATED INTRA-ABDOMINAL INFECTIONS BEFORE AND DURING THE PANDEMIC
- Open Access
- 15 June 2023
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 133 (12)
Hematopoietic progenitor kinase 1 inhibits the development and progression of pancreatic intraepithelial neoplasia
Ras plays an essential role in the development of acinar-to-ductal metaplasia (ADM) and pancreatic ductal adenocarcinoma (PDAC). However, mutant Kras is an inefficient driver for PDAC development. The mechanisms of the switching from low Ras activity to high Ras activity that are required for development and progression of pancreatic intraepithelial neoplasias (PanINs) are unclear. In this study, we found that hematopoietic progenitor kinase 1 (HPK1) was upregulated during pancreatic injury and ADM. HPK1 interacted with the SH3 domain and phosphorylated Ras GTPase-activating protein (RasGAP) and upregulated RasGAP activity. Using transgenic mouse models of HPK1 or M46, a kinase-dead mutant of HPK1, we showed that HPK1 inhibited Ras activity and its downstream signaling and regulated acinar cell plasticity. M46 promoted the development of ADM and PanINs. Expression of M46 in KrasG12D Bac mice promoted the infiltration of myeloid-derived suppressor cells and macrophages, inhibited the infiltration of T cells, and accelerated the progression of PanINs to invasive and metastatic PDAC, while HPK1 attenuated mutant Kras–driven PanIN progression. Our results showed that HPK1 plays an important role in ADM and the progression of PanINs by regulating Ras signaling. Loss of HPK1 kinase activity promotes an immunosuppressive tumor microenvironment and accelerates the progression of PanINs to PDAC.
- 15 June 2023
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 133 (12)
Open AccessHematopoietic progenitor kinase 1 inhibits the development and progression of pancreatic intraepithelial neoplasia
Ras plays an essential role in the development of acinar-to-ductal metaplasia (ADM) and pancreatic ductal adenocarcinoma (PDAC). However, mutant Kras is an inefficient driver for PDAC development. The mechanisms of the switching from low Ras activity to high Ras activity that are required for development and progression of pancreatic intraepithelial neoplasias (PanINs) are unclear. In this study, we found that hematopoietic progenitor kinase 1 (HPK1) was upregulated during pancreatic injury and ADM. HPK1 interacted with the SH3 domain and phosphorylated Ras GTPase-activating protein (RasGAP) and upregulated RasGAP activity. Using transgenic mouse models of HPK1 or M46, a kinase-dead mutant of HPK1, we showed that HPK1 inhibited Ras activity and its downstream signaling and regulated acinar cell plasticity. M46 promoted the development of ADM and PanINs. Expression of M46 in KrasG12D Bac mice promoted the infiltration of myeloid-derived suppressor cells and macrophages, inhibited the infiltration of T cells, and accelerated the progression of PanINs to invasive and metastatic PDAC, while HPK1 attenuated mutant Kras–driven PanIN progression. Our results showed that HPK1 plays an important role in ADM and the progression of PanINs by regulating Ras signaling. Loss of HPK1 kinase activity promotes an immunosuppressive tumor microenvironment and accelerates the progression of PanINs to PDAC.
- Open Access
- 30 April 2023
- Published by CMB Association in Cellular and Molecular Biology
- Vol. 69 (4) , 70-74
Effect of Maspin gene methylation induced by specific shRNA sequences on the proliferation of oral squamous cell carcinoma HN13 cells
It was to investigate the mechanism of Maspin gene methylation induced by specific shRNA primer sequences in the proliferation of oral squamous cell carcinoma (OSCC) cells. Human OSCC HN13 cell line was selected as the study object, and the corresponding specific shRNA primer sequences were designed to construct Maspin-shRNA recombinant adenovirus using human Maspin nucleotide sequences as the target gene, and it was transfected into HN13 cells. The growth curve, Maspin expression level, migration and invasion ability, and proliferation activity of the transfected cells were analyzed. The results showed that the growth efficiency of transfected cells was significantly improved, and the OD value at 450 nm of cells in the specific sequence group (SSG) was greater than that of cells in the non-specific sequence group (nSSG). Maspin methylation was higher in the SSG than in the nSSG (P < 0.05). The number of cell migration and invasion in the SSG were higher than those in the nSSG (P < 0.05). The proliferation activity of cells in the SSG was higher than that of cells in the nSSG (P < 0.05). It showed that specific shRNA sequences induced Maspin gene methylation to inhibit Maspin expression, thereby participating in the migration and invasion motility of oral squamous carcinoma cells and improving proliferative activity.
- 30 April 2023
- Published by CMB Association in Cellular and Molecular Biology
- Vol. 69 (4) , 70-74
Open AccessEffect of Maspin gene methylation induced by specific shRNA sequences on the proliferation of oral squamous cell carcinoma HN13 cells
It was to investigate the mechanism of Maspin gene methylation induced by specific shRNA primer sequences in the proliferation of oral squamous cell carcinoma (OSCC) cells. Human OSCC HN13 cell line was selected as the study object, and the corresponding specific shRNA primer sequences were designed to construct Maspin-shRNA recombinant adenovirus using human Maspin nucleotide sequences as the target gene, and it was transfected into HN13 cells. The growth curve, Maspin expression level, migration and invasion ability, and proliferation activity of the transfected cells were analyzed. The results showed that the growth efficiency of transfected cells was significantly improved, and the OD value at 450 nm of cells in the specific sequence group (SSG) was greater than that of cells in the non-specific sequence group (nSSG). Maspin methylation was higher in the SSG than in the nSSG (P < 0.05). The number of cell migration and invasion in the SSG were higher than those in the nSSG (P < 0.05). The proliferation activity of cells in the SSG was higher than that of cells in the nSSG (P < 0.05). It showed that specific shRNA sequences induced Maspin gene methylation to inhibit Maspin expression, thereby participating in the migration and invasion motility of oral squamous carcinoma cells and improving proliferative activity.
- Open Access
- 13 May 2022
- Published by Springer Nature in Nature Communications
- Vol. 13 (1) , 1-18
Rapid acceleration of KRAS-mutant pancreatic carcinogenesis via remodeling of tumor immune microenvironment by PPARδ
Pancreatic intraepithelial neoplasia (PanIN) is a precursor of pancreatic ductal adenocarcinoma (PDAC), which commonly occurs in the general populations with aging. Although most PanIN lesions (PanINs) harbor oncogenic KRAS mutations that initiate pancreatic tumorigenesis; PanINs rarely progress to PDAC. Critical factors that promote this progression, especially targetable ones, remain poorly defined. We show that peroxisome proliferator-activated receptor-delta (PPARδ), a lipid nuclear receptor, is upregulated in PanINs in humans and mice. Furthermore, PPARδ ligand activation by a high-fat diet or GW501516 (a highly selective, synthetic PPARδ ligand) in mutant KRASG12D (KRASmu) pancreatic epithelial cells strongly accelerates PanIN progression to PDAC. This PPARδ activation induces KRASmu pancreatic epithelial cells to secrete CCL2, which recruits immunosuppressive macrophages and myeloid-derived suppressor cells into pancreas via the CCL2/CCR2 axis to orchestrate an immunosuppressive tumor microenvironment and subsequently drive PanIN progression to PDAC. Our data identify PPARδ signaling as a potential molecular target to prevent PDAC development in subjects harboring PanINs.
- 13 May 2022
- Published by Springer Nature in Nature Communications
- Vol. 13 (1) , 1-18
Open AccessRapid acceleration of KRAS-mutant pancreatic carcinogenesis via remodeling of tumor immune microenvironment by PPARδ
Pancreatic intraepithelial neoplasia (PanIN) is a precursor of pancreatic ductal adenocarcinoma (PDAC), which commonly occurs in the general populations with aging. Although most PanIN lesions (PanINs) harbor oncogenic KRAS mutations that initiate pancreatic tumorigenesis; PanINs rarely progress to PDAC. Critical factors that promote this progression, especially targetable ones, remain poorly defined. We show that peroxisome proliferator-activated receptor-delta (PPARδ), a lipid nuclear receptor, is upregulated in PanINs in humans and mice. Furthermore, PPARδ ligand activation by a high-fat diet or GW501516 (a highly selective, synthetic PPARδ ligand) in mutant KRASG12D (KRASmu) pancreatic epithelial cells strongly accelerates PanIN progression to PDAC. This PPARδ activation induces KRASmu pancreatic epithelial cells to secrete CCL2, which recruits immunosuppressive macrophages and myeloid-derived suppressor cells into pancreas via the CCL2/CCR2 axis to orchestrate an immunosuppressive tumor microenvironment and subsequently drive PanIN progression to PDAC. Our data identify PPARδ signaling as a potential molecular target to prevent PDAC development in subjects harboring PanINs.
- 20 February 2022
- Vol. 44 (2) , 107-116
Alteration of imprinted genes and offspring organ development caused by environmental factors.
Imprinted genes are a special subset of about 100 genes, which are mainly expressed in the form of parental monoallelic genes, and play important roles in the growth and development of embryos. In recent years, it has been found that epigenetic modification of imprinted genes induced by environmental factors can cause fetal multi-organ dysplasia and even susceptibility to multiple diseases in adulthood, which also exhibit multi-generational inheritance. In this review, we summarize the effects of expression changes of imprinted genes on ontogenetic development and organ functions in late stage of life, and propose that abnormal epigenetic modification and expression of imprinted genes caused by environmental deleterious factors are important mechanisms for explaining the multi-organ dysplasia in offspring. Such mechanisms are greatly significant for understanding the phenotypic changes caused by alteration of imprinted gene expression during ontogeny and exploring early prevention and treatment strategies of diseases.
- 20 February 2022
- Vol. 44 (2) , 107-116
Alteration of imprinted genes and offspring organ development caused by environmental factors.
Imprinted genes are a special subset of about 100 genes, which are mainly expressed in the form of parental monoallelic genes, and play important roles in the growth and development of embryos. In recent years, it has been found that epigenetic modification of imprinted genes induced by environmental factors can cause fetal multi-organ dysplasia and even susceptibility to multiple diseases in adulthood, which also exhibit multi-generational inheritance. In this review, we summarize the effects of expression changes of imprinted genes on ontogenetic development and organ functions in late stage of life, and propose that abnormal epigenetic modification and expression of imprinted genes caused by environmental deleterious factors are important mechanisms for explaining the multi-organ dysplasia in offspring. Such mechanisms are greatly significant for understanding the phenotypic changes caused by alteration of imprinted gene expression during ontogeny and exploring early prevention and treatment strategies of diseases.
- Open Access
- 31 January 2022
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 23 (3) , 1645
Identifying the Metabolic Signatures of PPARD-Overexpressing Gastric Tumors
Peroxisome proliferator-activated receptor delta (PPARD) is a nuclear receptor known to play an essential role in regulation of cell metabolism, cell proliferation, inflammation, and tumorigenesis in normal and cancer cells. Recently, we found that a newly generated villin-PPARD mouse model, in which PPARD is overexpressed in villin-positive gastric progenitor cells, demonstrated spontaneous development of large, invasive gastric tumors as the mice aged. However, the role of PPARD in regulation of downstream metabolism in normal gastric and tumor cells is elusive. The aim of the present study was to find PPARD-regulated downstream metabolic changes and to determine the potential significance of those changes to gastric tumorigenesis in mice. Hyperpolarized [1-13C] pyruvate magnetic resonance spectroscopy, nuclear magnetic resonance spectroscopy, and liquid chromatography-mass spectrometry were employed for metabolic profiling to determine the PPARD-regulated metabolite changes in PPARD mice at different ages during the development of gastric cancer, and the changes were compared to corresponding wild-type mice. Nuclear magnetic resonance spectroscopy-based metabolomic screening results showed higher levels of inosine monophosphate (p = 0.0054), uracil (p = 0.0205), phenylalanine (p = 0.017), glycine (p = 0.014), and isocitrate (p = 0.029) and lower levels of inosine (p = 0.0188) in 55-week-old PPARD mice than in 55-week-old wild-type mice. As the PPARD mice aged from 10 weeks to 35 weeks and 55 weeks, we observed significant changes in levels of the metabolites inosine monophosphate (p = 0.0054), adenosine monophosphate (p = 0.009), UDP-glucose (p = 0.0006), and oxypurinol (p = 0.039). Hyperpolarized [1-13C] pyruvate magnetic resonance spectroscopy performed to measure lactate flux in live 10-week-old PPARD mice with no gastric tumors and 35-week-old PPARD mice with gastric tumors did not reveal a significant difference in the ratio of lactate to total pyruvate plus lactate, indicating that this PPARD-induced spontaneous gastric tumor development does not require glycolysis as the main source of fuel for tumorigenesis. Liquid chromatography-mass spectrometry-based measurement of fatty acid levels showed lower linoleic acid, palmitic acid, oleic acid, and steric acid levels in 55-week-old PPARD mice than in 10-week-old PPARD mice, supporting fatty acid oxidation as a bioenergy source for PPARD-expressing gastric tumors.
- 31 January 2022
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 23 (3) , 1645
Open AccessIdentifying the Metabolic Signatures of PPARD-Overexpressing Gastric Tumors
Peroxisome proliferator-activated receptor delta (PPARD) is a nuclear receptor known to play an essential role in regulation of cell metabolism, cell proliferation, inflammation, and tumorigenesis in normal and cancer cells. Recently, we found that a newly generated villin-PPARD mouse model, in which PPARD is overexpressed in villin-positive gastric progenitor cells, demonstrated spontaneous development of large, invasive gastric tumors as the mice aged. However, the role of PPARD in regulation of downstream metabolism in normal gastric and tumor cells is elusive. The aim of the present study was to find PPARD-regulated downstream metabolic changes and to determine the potential significance of those changes to gastric tumorigenesis in mice. Hyperpolarized [1-13C] pyruvate magnetic resonance spectroscopy, nuclear magnetic resonance spectroscopy, and liquid chromatography-mass spectrometry were employed for metabolic profiling to determine the PPARD-regulated metabolite changes in PPARD mice at different ages during the development of gastric cancer, and the changes were compared to corresponding wild-type mice. Nuclear magnetic resonance spectroscopy-based metabolomic screening results showed higher levels of inosine monophosphate (p = 0.0054), uracil (p = 0.0205), phenylalanine (p = 0.017), glycine (p = 0.014), and isocitrate (p = 0.029) and lower levels of inosine (p = 0.0188) in 55-week-old PPARD mice than in 55-week-old wild-type mice. As the PPARD mice aged from 10 weeks to 35 weeks and 55 weeks, we observed significant changes in levels of the metabolites inosine monophosphate (p = 0.0054), adenosine monophosphate (p = 0.009), UDP-glucose (p = 0.0006), and oxypurinol (p = 0.039). Hyperpolarized [1-13C] pyruvate magnetic resonance spectroscopy performed to measure lactate flux in live 10-week-old PPARD mice with no gastric tumors and 35-week-old PPARD mice with gastric tumors did not reveal a significant difference in the ratio of lactate to total pyruvate plus lactate, indicating that this PPARD-induced spontaneous gastric tumor development does not require glycolysis as the main source of fuel for tumorigenesis. Liquid chromatography-mass spectrometry-based measurement of fatty acid levels showed lower linoleic acid, palmitic acid, oleic acid, and steric acid levels in 55-week-old PPARD mice than in 10-week-old PPARD mice, supporting fatty acid oxidation as a bioenergy source for PPARD-expressing gastric tumors.
- Open Access
- 7 January 2020
- Published by Spandidos Publications in Oncology Letters
- Vol. 19 (3) , 2021-2027
Role of HSP27 in the multidrug sensitivity and resistance of colon cancer cells
Multidrug resistance in cancer cells is a primary factor affecting therapeutic efficacy. Heat shock 27 kD protein 1 (HSP27) is associated with cell apoptosis and resistance to chemotherapy. However, the mechanisms underlying HSP27‑associated pathways in colon cancer cells remain unclear. Therefore, the present study used short hairpin (sh) RNA to inhibit HSP27 expression in colon cancer cells in order to investigate the effects in vitro and in vivo. Flow cytometry was used to investigate cell apoptosis and a xenograft model was employed to examine the tumorigenesis. Protein expression was measured by Western blotting. The results revealed that suppression of HSP27 expression significantly increased cell apoptosis, inhibited tumor growth and enhanced sensitivity to the anti‑cancer agents 5‑fluorouracil (5‑FU) and vincristine (VCR). shHSP27 significantly decreased the expression of notch receptor 1 and the phosphorylation level of Akt and mTOR, and enhanced the effect of 5‑FU and VCR. In conclusion, HSP27 suppression enhanced the sensitivity of colon cancer cells to 5‑FU and VCR, and increased colon cancer cell apoptosis with and without chemotherapy. Therefore, the development of novel therapeutic agents that inhibit the expression of HSP27 may offer a new treatment option for colon cancer.
- 7 January 2020
- Published by Spandidos Publications in Oncology Letters
- Vol. 19 (3) , 2021-2027
Open AccessRole of HSP27 in the multidrug sensitivity and resistance of colon cancer cells
Multidrug resistance in cancer cells is a primary factor affecting therapeutic efficacy. Heat shock 27 kD protein 1 (HSP27) is associated with cell apoptosis and resistance to chemotherapy. However, the mechanisms underlying HSP27‑associated pathways in colon cancer cells remain unclear. Therefore, the present study used short hairpin (sh) RNA to inhibit HSP27 expression in colon cancer cells in order to investigate the effects in vitro and in vivo. Flow cytometry was used to investigate cell apoptosis and a xenograft model was employed to examine the tumorigenesis. Protein expression was measured by Western blotting. The results revealed that suppression of HSP27 expression significantly increased cell apoptosis, inhibited tumor growth and enhanced sensitivity to the anti‑cancer agents 5‑fluorouracil (5‑FU) and vincristine (VCR). shHSP27 significantly decreased the expression of notch receptor 1 and the phosphorylation level of Akt and mTOR, and enhanced the effect of 5‑FU and VCR. In conclusion, HSP27 suppression enhanced the sensitivity of colon cancer cells to 5‑FU and VCR, and increased colon cancer cell apoptosis with and without chemotherapy. Therefore, the development of novel therapeutic agents that inhibit the expression of HSP27 may offer a new treatment option for colon cancer.